

Financial news for MNK dated on 2020-06-11: Mallinckrodt Highlights Publication Of Findings From Medical Chart Study To Assess Use Of Terlipressin, Other Vasopressors In Hospitalized Patients With Hepatorenal Syndrome Type 1

Financial news for MNK dated on 2020-06-09: Mallinckrodt Completes Rolling Submission Of Biologics License Application For Stratagraft Regenerative Skin Tissue To FDA

Financial news for MNK dated on 2020-06-01: Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services

Financial news for MNK dated on 2020-05-19: Mallinckrodt shares are trading lower after JP Morgan downgraded the company's stock from Neutral to Underweight.

Financial news for MNK dated on 2020-05-19: JP Morgan Downgrades Mallinckrodt to Underweight

Financial news for MNK dated on 2020-05-13: New York Ag Says Will Issue New Subpoenas To Multiple Banks, Financial Institutions To Determine Where The Sacklers Stored Their Money Over The Years

Financial news for MNK dated on 2020-05-06: SVB Leerink Maintains Market Perform on Mallinckrodt, Raises Price Target of \$3

Financial news for MNK dated on 2020-05-05: Mallinckrodt shares are trading lower the company reported worse-than-expected Q1 sales.

Financial news for MNK dated on 2020-05-05: Mallinckrodt Q1 Adj. EPS \$1.640 Beats \$1.480 Estimate, Sales \$665.800M Miss \$693.310M Estimate

Financial news for MNK dated on 2020-05-04: Mallinckrodt's INOmax Study Ended Early Due to Achievement of its Primary Goal

Financial news for MNK dated on 2020-04-30: Mallinckrodt Says Is Supporting Investigator-Initiated Study At Massachusetts General Hospital To Assess Effectiveness Of Inhaled Nitric Oxide In Patients With Severe Acute Respiratory Distress Syndrome Due To COVID-19

Financial news for MNK dated on 2020-04-22: Mallinckrodt shares are trading higher after the company announced the FDA has approved for review its New Drug Application for Terlipressin.

Financial news for MNK dated on 2020-04-22: Mallinckrodt Announces FDA Filing Acceptance Of New Drug Application For Terlipressin For Treatment Of Hepatorenal Syndrome Type 1 (HRS-1)

Financial news for MNK dated on 2020-04-21: Mallinckrodt Shares Relatively Quiet But Saw Large Volume Spike; Hearing New York Governor Cuomo Says Initiated Admin. Proceedings, Filed Charges Against Co. Related To Opioid Crisis

Financial news for MNK dated on 2020-04-15: Mallinckrodt Highlights Publication Of Data On Acthar Gel (Repository Corticotropin Injection) From Its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study In Rheumatoid Arthritis (RA) In Rheumatology And Therapy

Financial news for MNK dated on 2020-04-07: Mallinckrodt Shares Resume Trade, Tick To Pre-Market High Of \$2.05, Pullback To \$1.90 Level

Financial news for MNK dated on 2020-04-07: Mallinckrodt 8-K Shows Details Of Indenture For Co. Organized Under Laws Of Grand Duchy Of Luxembourg, Dated Apr. 7, 2020

Financial news for MNK dated on 2020-04-07: UPDATE: Mallinckrodt Shares Halted With Code News Pending

Financial news for MNK dated on 2020-04-07: Mallinckrodt Shares Halted

Financial news for MNK dated on 2020-04-01: CFRA Maintains Hold on Mallinckrodt, Lowers Price Target to \$4

Financial news for MNK dated on 2020-04-01: Mallinckrodt PLC shares are trading higher after the company announced it received clearance from Health Canada to start on a pilot trial of high dose inhaled nitric oxide therapy for coronavirus infection and associated lung complications.

Financial news for MNK dated on 2020-04-01: Mallinckrodt And Novoteris Receive Clearance From Health Canada To Start Pilot Trial Of High-Dose Inhaled Nitric Oxide Therapy For Coronavirus Infection And Associated Lung Complications

Financial news for MNK dated on 2020-03-18: UPDATE: Defendants' Notice To Mallinckrodt Indicates CMS Action Could Delay Any Potential Suspension Of Co. From Medicaid Program Until Aug. 31

Financial news for MNK dated on 2020-03-18: Mallinckrodt Shares Fall To Session Low As Hearing Defendants In Acthar Case Informed Co. CMS To Refrain From Locking Co. Out Of Online Data Reporting System For Next 60 Days

Financial news for MNK dated on 2020-03-17: Mallinckrodt Completes Rolling Submission Of New Drug Application To FDA Terlipressin For Treatment Of Patients With Hepatorenal Syndrome Type 1 (HRS-1)

Financial news for MNK dated on 2020-03-12: Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies

Financial news for MNK dated on 2020-03-11: Mallinckrodt Announces NY State Attorney General Has Joined 47 Other State Attorneys In Supporting Previously-Announced Opioid Settlement Against Co. And Related Entities

Financial news for MNK dated on 2020-03-04: Mallinckrodt Highlights Publication Of New Data On Acthar Gel In Rheumatoid Arthritis, Systemic Lupus Erythematosus And Dermatomyositis/Polymyositis Published In Open Access Rheumatology: Research And Reviews

Financial news for MNK dated on 2020-03-02: Mallinckrodt Initiates Rolling Submission of New Drug Application to the FDA for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1, Expects Complete New Drug Application Submission Within Coming Months

Financial news for MNK dated on 2020-02-26: B of A Securities Maintains Underperform on Mallinckrodt, Raises Price Target to \$3

Financial news for MNK dated on 2020-02-25: Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 25, 2020: NIO, TUP, PANW, MRNA, MNK

Financial news for MNK dated on 2020-02-25: Mallinckrodt Q4 Adj. EPS \$2.40 Beats \$2.05 Estimate, Sales \$804.9M Beat \$772.52M Estimate

Financial news for MNK dated on 2020-02-25: UPDATE: Mallinckrodt Has Reached Agreement In Principle That Would Resolve All Opioid-Related Claims Against Co.

Financial news for MNK dated on 2020-02-25: Mallinckrodt Announces Agreement On Principle For Global Opioid Settlement And Associated Debt Refinancing Activities Through Chapter 11 Filing By Certain Specialty Generics-Focused Subsidiaries; Plaintiffs Would Receive \$1.6B

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Resume Trade, Continue To Rebound; Down 22% For Session

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Halted To The Upside On Fifth Circuit Breaker

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Resume Trade, Rebound Sharply From Session Low, Up 52% From Low, Still Down 25% For Session

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Halted On Fourth Circuit Breaker, Down ~40% For Session

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Halted On Circuit Breaker

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Resume Trade

Financial news for MNK dated on 2020-02-24: Mallinckrodt Shares Halted On Circuit Breaker, Down 11.3%

Financial news for MNK dated on 2020-02-14: CA Ag's Office Says 'Far Along In The Process Of Talks' And Still Negotiating With Distributors On Opioid Settlement

Financial news for MNK dated on 2020-02-14: Shares of opioid-related companies are trading lower following reports suggesting 21 states have rejected an \$18 billion offer to settle opioid litigation.

Financial news for MNK dated on 2020-01-27: Mallinckrodt PLC shares are trading lower sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 as of Sunday.

Financial news for MNK dated on 2020-01-24: Mallinckrodt shares are trading lower. Not currently seeing any company-specific news.

Financial news for MNK dated on 2020-01-22: Mallinckrodt shares are trading lower. Not currently seeing any company-specific news.

Financial news for MNK dated on 2020-01-21: Mallinckrodt shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock has rallied approximately 84% over the past 5 trading sessions.

Financial news for MNK dated on 2020-01-16: Mallinckrodt shares are trading higher on momentum following the company's Monday presentation at the JP Morgan Healthcare Conference, in which the company said it could pay off debt maturities and saw a favorable outcome in the Acthar dispute.

Financial news for MNK dated on 2020-01-15: Mallinckrodt PLC shares are trading higher on seemingly no company-specific news. NOTE: U.S. equities are trading higher ahead of today's signing of the U.S.-China phase one trade deal.

Financial news for MNK dated on 2019-12-16: Mallinckrodt Announces First Patient Enrolled In Phase 4 Trial Of Acthar Gel For Severe Keratitis

Financial news for MNK dated on 2019-12-10: S&P Sets CCC Rating On Mallinckrodt, Assigns Negative Outlook

Financial news for MNK dated on 2019-12-10: Mallinckrodt Announces Plans To Update Its Incentive Compensation Clawback Policy And Create Opioid Report; Actions Taken In Response To Approval Of Shareholder Proposals Presented At 2019 Annual General Meeting

Financial news for MNK dated on 2019-12-05: Mallinckrodt shares are trading lower amid weakness in the broader biotech space.

Financial news for MNK dated on 2019-11-27: Benzinga Pro's Stocks To Watch For Wednesday, Nov. 27th, 2019: DE, ADSK, GES, MNK, AMZN

Financial news for MNK dated on 2019-11-26: Brooklyn Federal Prosecutors Open Criminal Probe Of Opioid Manufacturers, Distributors; Mallinckrodt, AmerisourceBergen, Johnson & Johnson and Amneal Say They Have Received Subpoenas

Financial news for MNK dated on 2019-11-26: Mallinckrodt Highlights Data On Acthar Gel For Symptomatic Sarcoidosis Published In Therapeutic Advances in Respiratory Disease

Financial news for MNK dated on 2019-11-25: Mallinckrodt shares are trading higher. Not seeing any news to justify the price action.

Financial news for MNK dated on 2019-11-20: West Virginia Sues Opioid Makers Endo International And Mallinckrodt

Financial news for MNK dated on 2019-11-12: Mallinckrodt Highlights Presentation Of New Clinical Data From Evaluating Acthar Gel In Rheumatoid Arthritis

Financial news for MNK dated on 2019-11-11: Mallinckrodt Highlights Presentation Of Phase 3 Results From CONFIRM Study Of Terlipressin For HRS-1; Study Met Primary Endpoint

Financial news for MNK dated on 2019-11-07: Mallinckrodt Announces Data Publication On The Treatment Effectiveness Of Acthar Gel For Resolution Of Multiple Sclerosis Relapse In A U.S. Health Plan Population

Financial news for MNK dated on 2019-11-07: Mallinckrodt Highlights Publication Of Data On Treatment Effectiveness Of Acthar Gel For Resolution Of Multiple Sclerosis Relapse In US Health Plan Population

Financial news for MNK dated on 2019-11-05: Mallinckrodt PLC shares are trading lower after the company reported worse-than-expected Q3 sales results.

Financial news for MNK dated on 2019-11-05: Mallinckrodt Sees FY19 Adj. EPS \$8.50-\$8.70 vs \$8.48 Est.

Financial news for MNK dated on 2019-11-05: Mallinckrodt Q3 Adj. EPS \$2.07 Beats \$1.98 Estimate, Sales \$743.7M Miss \$774.73M Estimate

Financial news for MNK dated on 2019-11-04: Mallinckrodt shares are trading higher. The stock has been volatile amid lawsuits against opioid-related companies this year.

Financial news for MNK dated on 2019-10-31: Mallinckrodt Announces UVADEX Approved In Australia For Use With The THERAKOS CELLEX Photopheresis System For Treatment Of

Chronic Graft Versus Host Disease (cGvHD) And Skin Manifestations Of Cutaneous T-Cell Lymphoma (CTCL) In Adults

Financial news for MNK dated on 2019-10-23: Mallinckrodt shares are trading higher. Not seeing any news to justify the price action.

Financial news for MNK dated on 2019-10-22: Mallinckrodt PLC shares are trading higher on seemingly no company-specific news.

Financial news for MNK dated on 2019-10-21: Mallinckrodt Shares Spike ~6% On Heavy Volume As Teva Confirms Settlement In Track 1 Opioid Case

Financial news for MNK dated on 2019-10-21: Mallinckrodt To Present Results From Its Pivotal Phase 3 Confirm Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1) At The Liver Meeting 2019

Financial news for MNK dated on 2019-10-21: Mallinckrodt Reports Will Present Results From Pivotal Phase 3 CONFIRM Study In Late-Breaking Session At The Liver Meeting

Financial news for MNK dated on 2019-10-21: Shares of opioid-related drug companies are trading lower after the WSJ reported that a settlement has been reached in the opioid addiction lawsuit. The settlement is expected to be announced today.

Financial news for MNK dated on 2019-10-17: Shares of opioid-associated drug distributors are trading higher on continued momentum after it was reported McKesson, AmerisourceBergen, and Cardinal Health are in talks to settle opioid litigation for \$18 billion.

Financial news for MNK dated on 2019-10-14: Mallinckrodt PLC shares are trading lower on continued downward momentum. The stock has decreased roughly 30% in the last month.

Financial news for MNK dated on 2019-10-01: Benzinga Pro's Top 10 Most-Searches Tickers For Morning of Tuesday, October 01, 2019

Financial news for MNK dated on 2019-10-01: Mallinckrodt Announces Findings From Observational Registry To Assess Acthar Gel In MS Relapse; Results For Main Subsets Of Patients Were 'Highly Statistically Significant For All The Efficacy Endpoints'

Financial news for MNK dated on 2019-09-30: Benzinga Pro's Top 10 Most-Searches Tickers For Morning of Monday, September 30, 2019

Financial news for MNK dated on 2019-09-30: Mallinckrodt shares are trading higher after the company announced it settled opioid cases in Cuyahoga and Summit counties in Ohio.

Financial news for MNK dated on 2019-09-30: Mallinckrodt Finalizes Settlement to Resolve Opioid Cases with the Ohio Counties of Cuyahoga and Summit, Mallinckrodt to Pay \$24M in Cash and \$6M in Products

Financial news for MNK dated on 2019-09-24: Benzinga Pro's Top 10 Most-Searches Tickers For Morning of Tuesday, September 24, 2019

Financial news for MNK dated on 2019-09-23: Benzinga Pro's Top 10 Most-Searches Tickers For Morning of Monday, September 23, 2019

Financial news for MNK dated on 2019-09-23: Mallinckrodt's Phase 3 Trial of StrataGraft Regenerative Tissue in Patients with Deep Partial-Thickness Thermal Burns Met Both Primary Endpoints

Financial news for MNK dated on 2019-09-13: Mallinckrodt Highlights Findings From Analysis Suggesting Acthar Gel May Be A Cost-Effective Option Compared To Other Treatments For Multiple Sclerosis Relapse

Financial news for MNK dated on 2019-09-12: Mallinckrodt shares trading lower likely on continued profit taking following a 90% rally on Tuesday. Despite also paring gains on Wednesday, the stock is still up about 43% since announcing it will sell BioVectra to HIG Capital for \$250 million.

Financial news for MNK dated on 2019-09-11: Benzinga Pro's Top 10 Most-Searches Tickers For Morning of Wednesday., September 11, 2019

Financial news for MNK dated on 2019-09-11: Mallinckrodt PLC shares are trading lower as traders potentially took profits after the stock rose roughly 90% yesterday, following news that the company would sale H.I.G. Capital for \$250 million.

Financial news for MNK dated on 2019-09-10: Mallinckrodt CEO Says Co. Spends About \$40M A Year On Dealing With Opioid Lawsuits

Financial news for MNK dated on 2019-09-10: Mallinckrodt To Sell BioVectra Inc. To H.I.G. Capital For \$250M

Financial news for MNK dated on 2019-09-09: Stifel Maintains Hold on Mallinckrodt, Lowers Price Target to \$8

Financial news for MNK dated on 2019-09-06: Mallinckrodt shares trading higher following settlement in principle to resolve Track 1 opioid cases in Summit, Cuyahoga, Ohio. The company will pay \$24 million in cash and donate \$6 million in generic products.

Financial news for MNK dated on 2019-09-06: Mallinckrodt Shares Resume Trade, Now Up 17% For Session

Financial news for MNK dated on 2019-09-06: Mallinckrodt Announces Settlement In Principle To Resolve Track 1 Opioid Cases With Ohio Counties Of Cuyahoga And Summit; Co. To Pay \$24M In Cash And Donate \$6M In Generic Products, All Named Mallinckrodt Will Be Dismissed With Prejudice From Lawsuit

Financial news for MNK dated on 2019-09-06: Mallinckrodt Shares Halted, News Pending

Financial news for MNK dated on 2019-09-05: Mallinckrodt shares are trading lower on a report that the company hired the restructuring firm Latham & Watkins in the wake of multiple looming lawsuits. BMO Capital also downgraded the stock from Outperform to Market Perform.

Financial news for MNK dated on 2019-09-05: BMO Capital Downgrades Mallinckrodt to Market Perform

Financial news for MNK dated on 2019-09-04: Mallinckrodt shares are trading lower on a report that the company hired the restructuring firm Latham & Watkins in the wake of multiple looming lawsuits.

Financial news for MNK dated on 2019-09-04: Mallinckrodt Shares Down 19% After Hours; Hearing Co. Hired Restructuring Firm Latham & Watkins

Financial news for MNK dated on 2019-09-04: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wednesday., September 04, 2019

Financial news for MNK dated on 2019-08-30: Mallinckrodt shares are trading lower after the company borrowed \$95 million in revolving credit "to address cash needs that may arise in the future."

Financial news for MNK dated on 2019-08-28: Barclays Maintains Equal-Weight on Mallinckrodt, Lowers Price Target to \$5

Financial news for MNK dated on 2019-08-27: Mallinckrodt shares are trading lower after the company lost an appeal in the INOmax patent dispute with Praxair.

Financial news for MNK dated on 2019-08-27: Mallinckrodt Says Disappointed By Court's Decision Rejecting Patent Infringement Lawsuit Against Praxair's Nitric Oxide Drug Product Delivery System

Financial news for MNK dated on 2019-08-15: Mallinckrodt Reports Top-Line Results From Pivotal Phase 3 CONFIRM Trial Of Terlipressin In Patients With HRS-1: Met Primary Endpoint

Financial news for MNK dated on 2019-08-13: Mallinckrodt Highlights Publication Of Results Of Phase 1b Trial Of StrataGraft Regenerative Tissue In Burns; Reports Burns Did Not Require Surgical Harvest Of Healthy Skin By 28 Days

Financial news for MNK dated on 2019-08-12: Shares of several healthcare companies are trading lower in sympathy with the overall market as the Treasury yield continues to decline along with ongoing trade tensions with China.

Financial news for MNK dated on 2019-08-12: Mallinckrodt Reports First Patient Enrolled In Phase 2a Study Of MNK-6106 In Hepatic Cirrhosis, Chronic Hepatic Encephalopathy

Financial news for MNK dated on 2019-08-07: Mallinckrodt PLC shares are trading lower despite the company reporting better-than-expected Q2 EPS and sales results. The company also reported FY19 EPS guidance above analyst estimates.

Financial news for MNK dated on 2019-08-06: Mallinckrodt Cites Multidistrict Opioid Litigation Case In Ohio As Partly Responsible For Decision Not To Spin Off Generics Business

Financial news for MNK dated on 2019-08-06: Mallinckrodt Sees FY19 Adj. EPS \$8.40-\$8.70 vs \$8.24 Est.

Financial news for MNK dated on 2019-08-06: Mallinckrodt Q2 Adj. EPS \$2.53 Beats \$2.08 Estimate, Sales \$823.3M Beat \$815.9M Estimate

Financial news for MNK dated on 2019-07-18: UPDATE: Mallinckrodt Will Make \$5M Equity Investment In Silence Therapeutics

Financial news for MNK dated on 2019-07-18: Mallinckrodt, Silence Therapeutics Report Collaboration To Develop, Commercialize RNAi Therapeutics For Complement-Medicated Diseases

Financial news for MNK dated on 2019-07-16: Mallinckrodt Reports Halted Phase 2B Trial On Use Of Acthar Gel In Amyotrophic Lateral Sclerosis

Financial news for MNK dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for MNK dated on 2019-06-24: Mallinckrodt Announces 50% Enrollment for its Phase 2B Trial Investigating the Use of Acthar Gel in Amyotrophic Lateral Sclerosis

Financial news for MNK dated on 2019-06-13: Mallinckrodt Reports All Primary, Secondary Endpoints In Phase 4 Acthar Gel Rheumatoid Arthritis Trial, Will Present Data At EULAR

Financial news for MNK dated on 2019-06-11: Barclays Initiates Coverage On Mallinckrodt with Equal-Weight Rating, Announces \$11 Price Target

Financial news for MNK dated on 2019-06-05: BZ NOTE On Mallinckrodt Price Action Over Last Few Mins.: Seeing ~35.4% Short

Financial news for MNK dated on 2019-06-05: Mallinckrodt Shares Resume Trade, Spike Sharply Higher, Now Up 7.6%

Financial news for MNK dated on 2019-06-05: Mallinckrodt Shares Halted, News Pending

Financial news for MNK dated on 2019-05-31: Piper Jaffray Downgrades Mallinckrodt to Neutral, Lowers Price Target to \$9

Financial news for MNK dated on 2019-05-29: Mallinckrodt To Present Phase 4 Acthar Gel Clinical Trial Data At European Congress Of Rheumatology 2019

Financial news for MNK dated on 2019-05-28: Mallinckrodt Provides Update On Plans For Company Separation And Spin-Off of Specialty Generics Business

Financial news for MNK dated on 2019-05-22: Jefferies Downgrades Mallinckrodt plc Ordinary Shares to Hold, Lowers Price Target to \$15

Financial news for MNK dated on 2019-05-21: Mallinckrodt shares trading lower following news the company filed suit against the US Department Of Health And Human Services, Centers For Medicare, Medicaid Services to protect Medicaid patient access to its Acthar gel.

Financial news for MNK dated on 2019-05-21: Mallinckrodt Files Suit Against U.S. Department of Health and Human Services, and Centers for Medicare and Medicaid Services to Protect Medicaid Patient Access to Acthar(r) Gel

Financial news for MNK dated on 2019-05-14: Mallinckrodt Completes Enrollment If Phase 3 Terlipressin CONFIRM Trial

Financial news for MNK dated on 2019-05-07: Mallinckrodt Raises FY19 Adj. EPS Guidance From \$8.10-\$8.40 To \$8.30-\$8.60 vs \$8.21 Est.

Financial news for MNK dated on 2019-05-07: Mallinckrodt Q1 Adj. EPS \$1.94 Beats \$1.71 Estimate, Sales \$790.6M Beat \$768.6M Estimate

Financial news for MNK dated on 2019-05-06: Mallinckrodt Reports Interim Analysis Results For Phase 4 Registry Of INOmax Gas For Inhalation For Pulmonary Hypertension In Neonates

Financial news for MNK dated on 2019-05-02: Mallinckrodt To Present Open-Label Results From Phase 4 Acthar Gel Clinical Trial In Patients With Rheumatoid Arthritis At Annual European Congress Of Rheumatology In June

Financial news for MNK dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that

has almost no chance of passing'

Financial news for MNK dated on 2019-04-23: Mallinckrodt Reports Lupus Phase 4 Study For Acthar Gel Completes Enrollment In Difficult-To-Manage Population

Financial news for MNK dated on 2019-04-18: Mallinckrodt Reports Top-Line Results From Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants: 'Study showed oxygenation improvement and increased out-of-body perfusion duration'

Financial news for MNK dated on 2019-04-12: Mallinckrodt Reports Completion Of Full Enrollment Of Phase 3 Trial For StrataGraft

Financial news for MNK dated on 2019-04-11: Mallinckrodt And Washington University St. Louis Select First Collaborative Research Endeavor

Financial news for MNK dated on 2019-04-09: Mallinckrodt Gives an Update on its Acthar Gel

Financial news for MNK dated on 2019-03-20: SunTrust Robinson Humphrey Initiates Coverage On Mallinckrodt with Hold Rating, Announces \$23 Price Target

Financial news for MNK dated on 2019-03-18: Mallinckrodt Announces Bryan Reasons CFO

Financial news for MNK dated on 2019-02-26: Mallinckrodt shares are trading higher after the company reported better than expected Q4 results and announced strong 2019 guidance.

Financial news for MNK dated on 2019-02-26: Mallinckrodt Sees FY19 Adj. EPS \$8.10-\$8.40 vs \$7.37 Estimate, Sales Growth For Special Brands, Specialty Generics, Amitiza Units 1-4%

Financial news for MNK dated on 2019-02-26: Mallinckrodt Q4 EPS \$2.18 Beats \$1.92 Estimate, Sales \$834.9M Beat \$636.7M Estimate

Financial news for MNK dated on 2019-02-25: Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune

Financial news for MNK dated on 2019-02-20: Mallinckrodt Announces Interim Analysis Results For Therakos Platform Phase 3 Clinical Trial In Treatment Of Pediatric Patients With Steroid Refractory Acute Graft-versus-Host Disease; Overall Response Rate Exceeded Specified Study Midpoint Target

Financial news for MNK dated on 2019-02-05: Mallinckrodt Offers Update On Phase 4 Data HP Acthar Gel: 'primary end point results consistent with prior reports that showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity'

Financial news for MNK dated on 2019-01-03: Mallinckrodt Reports Data From Its HP Acthar Gel In Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation

Financial news for MNK dated on 2018-12-21: Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy;

Financial news for MNK dated on 2018-12-12: Mallinckrodt shares are now trading slightly higher, rebounding from premarket losses after the FDA informed the company that its New Drug Application for Roxicodone will need additional evaluation.

Financial news for MNK dated on 2018-12-12: Mallinckrodt shares are trading lower after the FDA informed Mallinckrodt that its New Drug Application for Roxicodone will need additional evaluation.

Financial news for MNK dated on 2018-12-12: Mallinckrodt's SpecGx Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation Of Roxicodone; In Letter, FDA Provided Guidance Regarding Areas Needing Further Evaluation For Resubmission

Financial news for MNK dated on 2018-12-06: UPDATE: Mallinckrodt Says Spun Off Specialty Generics Unit Will Be Listed On NYSE, Will Assume Mallinckrodt Name, Ticker Symbol

Financial news for MNK dated on 2018-12-06: UPDATE: Mallinckrodt Says Planned Separation Of Specialty Generics Unit To Be Executed Through Pro-Rata Distribution Of Common Stock To Co.'s Shareholders; Spin Off Expected To Be Completed In 2H'19 Or Sooner

Financial news for MNK dated on 2018-12-06: Mallinckrodt Reports Spin Off Of Its Specialty Generics Unit

Financial news for MNK dated on 2018-11-26: 'More \$MNK failed clinical studies comes weeks after OIG publishes that Acthar is a drug based on a history of "fraud and abuse. Citron believes that \$MNK could be first pharma to go BK if Medicare opens its eyes' -Citron Research Tweets

Financial news for MNK dated on 2018-11-26: '\$MNK has just FAILED it's only real clinical trial of Acthar. Mallinckrodt has failed to disclose. Citron will follow with the full story on why the OIG and MEDPAC are finally about to put an end to this charade.' -Citron Research Tweets

Financial news for MNK dated on 2018-11-19: Canaccord Genuity Upgrades Mallinckrodt to Buy, Raises Price Target to \$40

Financial news for MNK dated on 2018-11-14: Mallinckrodt's SpecGx Reports FDA Voted 10-7 To Approve Its Abuse-Deterrent Roxicodone; Committee Voted 12-5 To Label Drug As Abuse-Deterrent By Nasal Route, Voted 10-7 Drug Should Not Be Labeled Abuse-Deterrent By Intravenous Route

Financial news for MNK dated on 2018-11-14: 13F From Paulson & Co. Shows Liquidated Stakes In Vistra Energy, CenturyLink, Raises Stakes In NXP Semi, Aetna, Altaba, Cut Stakes In T-Mobile, Mallinckrodt, AT&T

Financial news for MNK dated on 2018-11-08: Mallinckrodt Reports Earned Int'l. Standard ISO 13485:2016, Medical Device Single Audit Program Certifications For INOmax DSIR Plus Nitric Oxide Delivery Systems

Financial news for MNK dated on 2018-11-06: Mallinckrodt PLC Sees FY18 Adj. EPS \$7.00-\$7.20 vs \$6.75 Est.

Financial news for MNK dated on 2018-11-06: Mallinckrodt PLC Q3 Adj. EPS \$2.10 Beats \$1.79 Estimate, Sales \$640M Beat \$634.52M Estimate

Financial news for MNK dated on 2018-10-26: Mallinckrodt Reports First Patient Screened In Phase 4 Trial Of HP Acthar Gel For Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Financial news for MNK dated on 2018-10-22: Mallinckrodt Presents Data on H.P. Acthar Gel in Rheumatoid Arthritis at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting

Financial news for MNK dated on 2018-10-15: Benzinga Pro's Top 10 Most-Searched Tickers For The Morning Of Mon., Oct. 15, 2018

Financial news for MNK dated on 2018-10-15: Mallinckrodt's Stratatech Company Awarded \$26M in Additional BARDA Funding for Pediatric Studies of StrataGraft Skin Tissue in Thermal Burns

Financial news for MNK dated on 2018-10-12: 13G Filing Shows Mallinckrodt Reporting 5.1% Stake Taken By D.E. Shaw

Financial news for MNK dated on 2018-10-09: FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines'

Financial news for MNK dated on 2018-10-08: Mallinckrodt Announces the FDA Will Hold a Meeting of its Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee on Nov. 14 to Assess the 505(b)2 New Drug Application

Financial news for MNK dated on 2018-10-04: Hearing Stifel Out In Defense Of Mallinckrodt, Says Praxair System Will Be Another Branded Competitor, Not A Generic Substitute

Financial news for MNK dated on 2018-09-21: Mallinckrodt Option Alert: Oct 19 \$31 Calls Sweep (18) near the Ask: 500 @ \$1.2 vs 59 OI; Earnings 11/6 Before Open [est] Ref=\$29.835

Financial news for MNK dated on 2018-09-18: FDA Issues New Safety Measures For Immediate-Release, Extended-Release, and Long-Acting Opioid Analgesics

Financial news for MNK dated on 2018-09-14: Berenberg Initiates Coverage On Mallinckrodt with Sell Rating, Announces \$25 Price Target

Financial news for MNK dated on 2018-09-11: Goldman Sachs Downgrades Mallinckrodt to Sell, Raises Price Target to \$28

Financial news for MNK dated on 2018-08-23: Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy, Trial To Commence

In The Coming Months With The First Patients Enrolled In The U.S.

Financial news for MNK dated on 2018-08-22: Mallinckrodt Confirms Receipt Of Complete Response Letter Stannsoporfin

Financial news for MNK dated on 2018-08-22: REMINDER: Mallinckrodt Has FDA PDUFA Decision Date Today for Stannsoporfin; BZ NOTE: FDA AdCom Meeting May 3rd Voted 3-21 Against Approval

Financial news for MNK dated on 2018-08-17: Morgan Stanley Maintains Equal-Weight on Mallinckrodt, Raises Price Target to \$35

Financial news for MNK dated on 2018-08-08: Barclays Maintains Underweight on Mallinckrodt, Raises Price Target to \$20

Financial news for MNK dated on 2018-08-08: Stifel Nicolaus Maintains Hold on Mallinckrodt, Raises Price Target to \$30

Financial news for MNK dated on 2018-08-08: Raymond James Downgrades Mallinckrodt to Market Perform

Financial news for MNK dated on 2018-08-07: Mallinckrodt Raises FY18 Adj. EPS Outlook From \$6.50-\$6.90 vs \$6.23 Est.

Financial news for MNK dated on 2018-08-07: Mallinckrodt Q2 Adj. EPS \$1.78 Beats \$1.48 Estimate, Sales \$631.7M Beat \$620.42M Estimate

Financial news for MNK dated on 2018-08-06: Mallinckrodt Forms Collaborative Research Partnership With Washington University in St. Louis With Focus On Rare Disease; Co. Fund Up To \$10M In Research Grants Over 5-yr Period

Financial news for MNK dated on 2018-08-02: Mallinckrodt Announces Enrollment of the First Patient in its Phase 2 Duchenne Muscular Dystrophy Trial

Financial news for MNK dated on 2018-08-01: Mallinckrodt Initiates Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants

Financial news for MNK dated on 2018-07-19: Canaccord Genuity Maintains Hold on Mallinckrodt, Raises Price Target to \$22

Financial news for MNK dated on 2018-07-09: New Health Economic Data on Mallinckrodt's OFIRMEV Injection Published in Journal of Knee Surgery

Financial news for MNK dated on 2018-06-29: Mallinckrodt Option Alert: Aug 17 \$15 Puts Sweep (3) near the Ask: 12191 @ \$0.901 vs 46 OI; Earnings 8/7 Before Open [est] Ref=\$18.9

Financial news for MNK dated on 2018-06-29: Mallinckrodt Option Alert: Jan 18 \$15 Puts Sweep (18) near the Ask: 550 @ \$1.798 vs 5175 OI; Earnings 8/7 Before Open [est] Ref=\$18.97

Financial news for MNK dated on 2018-06-29: Mallinckrodt Option Alert: Aug 17 \$12.5 Puts Sweep (21) near the Ask: 973 @ \$0.346 vs 0 OI; Earnings 8/7 Before Open [est] Ref=\$18.99

Financial news for MNK dated on 2018-06-29: Traders Circulating Negative CNN Article On Mallinckrodt's Acthar Gel Titled 'Medicare spent \$2 billion for one drug as the manufacturer paid doctors millions'

Financial news for MNK dated on 2018-06-28: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel Achieves its Enrollment Target

Financial news for MNK dated on 2018-06-18: Mallinckrodt Up 0.5% At \$19.08, Hearing Suntrust Raised Mallinckrodt Price Target From \$14 To \$25

Financial news for MNK dated on 2018-06-18: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel Studies

Financial news for MNK dated on 2018-05-17: BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business By Reconstructing The Board; Also Announced A \$50M Equity Financing Deal Led By Broadfin

Financial news for MNK dated on 2018-05-08: Mallinckrodt Q2 EPS \$1.31 Beats \$1.10 Estimate, Sales \$572.6M Beat \$569.61M Estimate

Financial news for MNK dated on 2018-05-07: Mallinckrodt Pharma Posts a Response to 60 Minutes Regarding its HP Acthar Gel

Financial news for MNK dated on 2018-05-04: UPDATE: Mallinckrodt Is Not Specifically

Mentioned In CBSpressexpress.com Listings For Sun., May 6 '60 Minutes'; However, Site Does Highlight 'The Rockford File' Describing City Of Rockford, Illinois Suit Against Co.

Financial news for MNK dated on 2018-05-04: Mallinckrodt Shares Largely Unaffected As Traders Circulate Word Of Negative '60 Minutes' Piece This Sunday

Financial news for MNK dated on 2018-05-03: Stocks That Made New 52-Week Lows Today Include Colgate-Palmolive, Philip Morris, Regeneron, Corning, Hanesbrands, Bed Bath & Beyond, Pepsi, Coca-Cola, Paccar, Johnson & Johnson, Mallinckrodt, CBS, DISH Network, Goodyear Tire, Chubb, Hershey, and AT&T

Financial news for MNK dated on 2018-05-03: REMINDER: Mallinckrodt Has FDA AdCom Mtg. Today for Stannsoporfin

Financial news for MNK dated on 2018-05-02: B. Riley FBR Initiates Coverage On Mallinckrodt with Neutral Rating, Announces \$15 Price Target

Financial news for MNK dated on 2018-05-01: Stocks That Made New 52-Week Low Today Include: CBS, Goodyear Tire, Vulcan Materials, Regeneron, Hershey, Leggett & Platt, Harley-Davidson, Kraft Heinz, Kellogg, Mallinckrodt, Fortune Brands Home, Comcast, Pepsi, and Acuity Brands

Financial news for MNK dated on 2018-04-23: Stocks That Made New 52-Week Lows Today Include: Kimberly-Clark, Philip-Morris, CenterPoint Energy, Fortune Brands Home, Mallinckrodt, Clorox, Bristol-Myers, Simon Property Group, Pepsi, Kimco Realty, Hasbro, and Procter & Gamble

Financial news for MNK dated on 2018-04-16: Mallinckrodt Reports \$300M Repayment Of Unsecured, Fixed-Rate Notes Maturing Apr. 15, 2018 With Cash On Hand

Financial news for MNK dated on 2018-04-12: Stifel Nicolaus Downgrades Mallinckrodt to Hold

Financial news for MNK dated on 2018-04-12: Shares Of Mallinckrodt Down 8.6% Following Chatter Of Stifel Downgrade

Financial news for MNK dated on 2018-04-12: UPDATE: Wells Fargo Says Mallinckrodt Has Indicated It Will Defend Itself 'Vigorously'

Financial news for MNK dated on 2018-04-12: Mallinckrodt Shares Down 7.5%; Wells Fargo Highlights News Of Whistleblower Suit Being Made Public, Says Spoke With Co. Investor Relations And Mgmt. 'Strongly Disagrees' With Allegations

Financial news for MNK dated on 2018-04-12: SunTrust Robinson Humphrey Initiates Coverage On Mallinckrodt with Hold Rating, Announces \$15.00 Price Target

Financial news for MNK dated on 2018-04-04: Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018

Financial news for MNK dated on 2018-04-03: Stocks That Made New 52-Wk Lows Today Include: Incyte, Merck, Mallinckrodt, Celgene, Cerner, Willams Cos., AMD, Albemarle, Kinder Morgan, Western Union, Walgreens, Kraft Heinz, Nielsen, and Alliance Data Systems

Financial news for MNK dated on 2018-04-02: Stocks That Made New 52-Wk Lows Today Include: Johnson Controls, Exxon Mobile, Walgreens, Mallinckrodt, Hasbro, AMD, General Mills, Goodyear Tire, Whirlpool, Kraft Heinz, AIG, and Signet Jewelers

Financial news for MNK dated on 2018-03-28: Mallinckrodt To Report Q1 Earnings On Tues., May 8, 2018 Before Market Open

Financial news for MNK dated on 2018-02-28: Benzinga Pro's Top 10 Most-Searches Tickers Wed. Morning: Square, Lipocine, Macy's, Mallinckrodt, Tetrphase Pharma, Zosano Pharma, Arcadia Biosciences, DelMar Pharma, Akers Biosciences, Acorn

Financial news for MNK dated on 2018-02-27: Mallinckrodt Shares Up 25% Following Strong Q4 Earnings Beat But FY18 EPS Guidance Below Estimates

Financial news for MNK dated on 2018-02-27: Mallinckrodt FY18 EPS \$6.00-\$6.50 vs \$7.14 Est., Sales Growth Of 3-6%

Financial news for MNK dated on 2018-02-27: Mallinckrodt Reports Q4 EPS \$2.01 vs \$1.69 Est., Sales \$792M vs \$774M Est.

Financial news for MNK dated on 2018-02-23: Mallinckrodt Reports Received FDA Acceptance Of Stannsoporfin NDA Filing

Financial news for MNK dated on 2018-02-14: Mallinckrodt Enrolls First Patient in

Phase 1 Study of ExpressGraft C9T1 Skin Tissue

Financial news for MNK dated on 2018-02-06: S&P Dow Jones Indices Reports 'Boyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600'

Financial news for MNK dated on 2018-02-02: Barclays Downgrades Mallinckrodt to Underweight

Financial news for MNK dated on 2018-01-30: Mallinckrodt Announces First Patient Enrolled In Phase 4 Trial Of HP Acthat Gel For Pulmonary Sarcoidosis

Financial news for MNK dated on 2018-01-11: Cantor Out With Note On Endo, Says Oxymorphone Subpoena May Not Hurt That Much And Is Isolated To Endo For Now, But More Co.'s Could Be The Target To Investigations Over Time Including Teva, Mylan, Impax, Mallinckrodt, Allergan

Financial news for MNK dated on 2018-01-08: UPDATE: Mallinckrodt, Baxter Deal For RECOTHROM, PREVELEAK Will Include Upfront Payment Of \$153M

Financial news for MNK dated on 2018-01-08: Mallinckrodt Reports Will Sell RECOTHROM, PREVELEAK To Baxter For ~\$185M

Financial news for MNK dated on 2018-01-04: Mallinckrodt Completes Stannsoporfin NDA

Financial news for MNK dated on 2018-01-03: Leerink Swann Initiates Coverage On Mallinckrodt with Market Perform Rating, Announces \$26.00 Price Target

Financial news for MNK dated on 2017-12-27: Maxim Says They're Disappointed In Sucampo Pharmaceuticals Takeout Value, But Believes All Interested Parties On Sucampo's Side Will See Deal As A 'Happy Exit'; Believes Mallinckrodt Is Receiving A Great Deal For Co. At This Stage

Financial news for MNK dated on 2017-12-26: Cantor Out Positive On Mallinckrodt, Says Sucampo Deal Was Smart And Strategic; Helps Co. Advance Towards Vision Of Becoming An 'Innovation-Driven specialty Pharmaceutical Growth Company'

Financial news for MNK dated on 2017-12-26: Mallinckrodt's Acquisition of Sucampo is a Cash Offer

Financial news for MNK dated on 2017-12-26: Mallinckrodt to Acquire Sucampo Pharma for \$18/Share

Financial news for MNK dated on 2017-12-22: Mallinckrodt Says the New Tax Bill Will be Neutral to Slightly Positive for the Company, Sees a Deferred Tax Benefit for \$450M to \$500M

Financial news for MNK dated on 2017-12-22: Mallinckrodt Halted, News Pending

Financial news for MNK dated on 2017-12-20: Mallinckrodt, Insys Move Lower; Hearing Traders Circulating Chatter That New Mexico Is Suing Companies Over Opioid Epidemic

Financial news for MNK dated on 2017-12-11: UPDATE: Mallinckrodt Sees Dilution From Ocrea Purchase To Adj. EPS \$0.25-\$0.35 Annually Beginning In '18

Financial news for MNK dated on 2017-12-11: Mallinckrodt Reports Closing Of Ocera Therapeutics Deal

Financial news for MNK dated on 2017-11-22: Oppenheimer Downgrades Mallinckrodt PLC to Perform

Financial news for MNK dated on 2017-11-13: Form 4 Filing Shows Mallinckrodt Director Booth Purchased 10K Shares At Weighted Avg. Price \$21.8236

Financial news for MNK dated on 2017-11-13: Form 4 Filings Show Mallinckrodt Director Gulyas Purchased 1.5K Shares At \$21.30, Director Zaccagnino Purchased 5K Shares AT \$21.30

Financial news for MNK dated on 2017-11-13: Form 4 Filing Shows Mallinckrodt Director Reed Purchased 1K Shares At \$21.50

Financial news for MNK dated on 2017-11-13: Form 4 Filing Shows Mallinckrodt EVP, Chief Scientific Officer Romano Purchased 2K Shares At \$21.96

Financial news for MNK dated on 2017-11-13: James Flynn Reports 6.07% Stake In Mallinckrodt

Financial news for MNK dated on 2017-11-08: Canaccord Genuity Maintains Hold on Mallinckrodt PLC, Lowers Price Target to \$24.00

Financial news for MNK dated on 2017-11-08: Morgan Stanley Maintains Equal-Weight on Mallinckrodt PLC, Lowers Price Target to \$27.00

Financial news for MNK dated on 2017-11-08: Goldman Sachs Downgrades Mallinckrodt PLC to Neutral

Financial news for MNK dated on 2017-11-08: Wells Fargo Downgrades Mallinckrodt PLC to Market Perform

Financial news for MNK dated on 2017-11-08: Stifel Nicolaus Maintains Buy on Mallinckrodt PLC, Lowers Price Target to \$50.00

Financial news for MNK dated on 2017-11-08: Barclays Downgrades Mallinckrodt PLC to Equal-Weight

Financial news for MNK dated on 2017-11-07: Unconfirmed, Hearing Mallinckrodt Downgraded At Deutsche Bank

Financial news for MNK dated on 2017-11-07: Mallinckrodt Q3 Adj. EPS \$1.97 vs \$1.81 Est., Sales \$793.9M vs \$812.0M Est.

Financial news for MNK dated on 2017-11-02: Ocera Therapeutics Shares Up 66% Following \$1.52/Share Offer From Mallinckrodt; Stock Currently Trading 11% Above Offer Price

Financial news for MNK dated on 2017-11-02: Ocerta Therapeutics to be Acquired by Mallinckrodt for \$1.52/Share

Financial news for MNK dated on 2017-10-09: Mallinckrodt Says it Will do a Phase 4 Study of HP Acthar Gel

Financial news for MNK dated on 2017-10-05: Canaccord Genuity Downgrades Mallinckrodt plc Ordinary Shares to Hold

Financial news for MNK dated on 2017-10-04: Mallinckrodt Downgraded From Buy To Hold At Canaccord Genuity, Price Target Cut From \$77 To \$40 - Reuters

Financial news for MNK dated on 2017-10-04: REMINDER: Mallinckrodt Holding Investor Briefing Today 9:30am ET

Financial news for MNK dated on 2017-10-04: Mallinckrodt Expects its Total Pipeline Net Sales to Exceed \$1B

Financial news for MNK dated on 2017-10-04: Mallinckrodt Expects Net Sales of Near-Term Development Programs to Exceed \$675M

Financial news for MNK dated on 2017-10-02: UPDATE: Mallinckrodt Sees Dilution Of \$0.10-\$0.15/Share To Adj. EPS Figure For Remainder Of 2017; Sees Modestly Lower Dilution In 2018

Financial news for MNK dated on 2017-10-02: UPDATE: Mallinckrodt Says NeuroproteXeon Will Receive Upfront Payment Of \$10M From Co.; Includes Added Payments Of Up To \$25M Dependent On Development, Regulatory, Sales Milestones

Financial news for MNK dated on 2017-10-02: UPDATE: Mallinckrodt Highlights FDA SPA Approved For Phase 3 Trial Will Begin In Early 2018; FDA Orphan Drug Designation Granted For Inhaled Xenon Gas Therapy

Financial news for MNK dated on 2017-10-02: Mallinckrodt Reports Licensing Of Inhaled Xenon Gas Therapy Development Product

Financial news for MNK dated on 2017-09-28: Goldman Sachs Initiates Coverage On Mallinckrodt plc Ordinary Shares with Buy Rating, Announces \$55.00 Price Target

Financial news for MNK dated on 2017-09-14: Mallinckrodt Shares Earlier Moved Up As Much As 3.5% Following Circulation Of Chatter Co. Cancelled Out Of Deutsche Bank Conference; BZ NOTE: Numerous Cos. Cancelled Out Of Presentation -- At Least 45 Cos.

Financial news for MNK dated on 2017-09-14: UPDATE: Hearing Mallinckrodt Chatter Related To Co. Cancelling Presentation For Deutsche Bank

Financial news for MNK dated on 2017-09-13: Mizuho Downgrades Mallinckrodt plc Ordinary Shares to Neutral, Lowers Price Target to \$40.00

Financial news for MNK dated on 2017-09-12: Mallinckrodt Shares Turn Negative, Down ~0.2% For Session As Kynikos' Jim Chanos Currently On CNBC's 'Fast Money: Halftime Report' Discussing Co./Stock

Financial news for MNK dated on 2017-09-06: Morgan Stanley Downgrades Mallinckrodt plc Ordinary Shares to Equal-Weight

Financial news for MNK dated on 2017-08-08: Mallinckrodt Q2 EPS \$0.72 vs \$1.73 Est., Sales \$824.5M vs \$829.6M Est., May Not Compare

Financial news for MNK dated on 2017-08-04: Mallinckrodt Reports InfaCare Pharma And Stannsoporfin For Upfront Payment Of \$80M Plus Added Payments Of \$345M Upon Regulatory, Sales Milestones

Financial news for MNK dated on 2017-08-01: Mallinckrodt Enrolls Initial Patient In Phase 4 Registry Of INOMAX Gas For Inhalation For Pulmonary Hypertension In Neonates

Financial news for MNK dated on 2017-07-19: UPDATE: ResMed, Packaging Corp. Of America, AO Smith, Duke Realty To Replace Mallinckrodt, Murphy Oil, Bed Bath & Beyond, Transocean In S&P 500

Financial news for MNK dated on 2017-07-18: Mallinckrodt's StrataGraft is Designated as Regenerative Medicine Advanced Therapy by the FDA

Financial news for MNK dated on 2017-07-13: Mallinckrodt Announces Terlipressin Phase 3 Trial Achieves enrollment Target Ahead Of Schedule

Financial news for MNK dated on 2017-07-13: Mallinckrodt PLC Shares Up 2% After The Company Disclosed The FDA Has Granted Orphan Drug Designation For Potential DMD Treatment

Financial news for MNK dated on 2017-07-12: Watching Sarepta Shares Following News Mallinckrodt Won Orphan Drug Designation For DMD Treatment

Financial news for MNK dated on 2017-07-12: Mallinckrodt Reports FDA Granted Orphan Drug Designation For Development Product For Potential DMD Treatment

Financial news for MNK dated on 2017-07-11: Mallinckrodt Responds Following Settlement: Reaffirms 'Commitment to Ensuring Safe and Appropriate Use of its Specialty Generic Opioid Products,' Highlights 'Settlement Contains No Admission of Liability for Civil Penalties for Relevant Conduct'

Financial news for MNK dated on 2017-06-23: Citron Research Publishes Letter To Congress Regarding 'The Truth About Acthar'

Financial news for MNK dated on 2017-06-22: Citron Research Tweets: \$MNK Breaking News from the FDA FAERS database. Adverse events from Acthar up over 280% Not an opinion- FACT. citronresearch.com

Financial news for MNK dated on 2017-06-22: Mallinckrodt Statement on H.P. Acthar Gel Update

Financial news for MNK dated on 2017-06-20: UPDATE: Imprimis CEO Mark Baum Tells Benzinga Eton Spin-Off Will Respond To FDA Pharma Competition Concerns, Improve Competition Against 2 'Expensive drugs without competition: Mallinckrodt's H.P. Acthar gel and Endo's Xiaflex'

Financial news for MNK dated on 2017-06-16: Cantor Fitzgerald Initiates Coverage On Mallinckrodt plc Ordinary Shares with Overweight Rating, Announces \$52.00 Price Target

Financial news for MNK dated on 2017-06-14: Mallinckrodt Enrolls 1st Patient In Phase 2B Trial Of Acthar Gel

Financial news for MNK dated on 2017-06-13: Mallinckrodt Shares Volatile Premarket As Traders Circulating Comment From Wells Fargo Suggesting Co. Is Exploring Options, Including Going Private; Stock Currently Up 1.1% But Well Off Pre-Market High

Financial news for MNK dated on 2017-06-07: Mallinckrodt Reports Enrollment of First Patient in Phase 3 Trial of StrataGraft

Financial news for MNK dated on 2017-06-06: Intellipharma Reports Launch of Generic Seroquel XR by Mallinckrodt

Financial news for MNK dated on 2017-06-05: Citron Publishes 'Citron provides New PROOF (post-SALT Conference) why Mallinckrodt is on its way to ZERO'

Financial news for MNK dated on 2017-06-05: Citron Research Tweets: \$MNK BK Citron exposes NEW info. \$ESRX speaks about Acthar. Respect To Chanos. First Enron then \$VRX Now \$MNK <http://citronresearch.com>

Financial news for MNK dated on 2017-05-30: Mallinckrodt Said To Be Exploring Sale Of Generic Drug Division

Financial news for MNK dated on 2017-05-26: Mallinckrodt Shares Largely Unaffected After FDA Denies Mallinckrodt Citizens Petition Regarding INOMAX

Financial news for MNK dated on 2017-05-25: Mallinckrodt Announces First Patients in Prospective Observational Registry on Use of HP Acthar Gel Following Acute Multiple Sclerosis Relapse

Financial news for MNK dated on 2017-05-23: Mallinckrodt Reports First Patient Enrolled In Phase 4 Trial Of HP Acthar Gel For Multiple Sclerosis

Financial news for MNK dated on 2017-05-19: Mallinckrodt Spokesperson on Chanos' Short Thesis: 'Specific to Express Scripts, Mallinckrodt has arms-length contracts for services with Express Scripts'

Financial news for MNK dated on 2017-05-19: Mallinckrodt Spokesperson on Chanos' Short Thesis, Differences Between MNK-1411, Acthar: '...the regulatory path for any corticotropin-type new drug application would require FDA approval, which could take years.'

Financial news for MNK dated on 2017-05-19: Mallinckrodt Spokesperson on Chanos' Short Thesis: 'MNK-1411...is not a 'generic competitor to Acthar.' They are two very different drugs.'

Financial news for MNK dated on 2017-05-19: Mallinckrodt Spokesperson Refutes Chanos' Short Thesis: 'Though Acthar is a significant contributor to Mallinckrodt's overall profitability, it is substantially less than the asserted estimates'

Financial news for MNK dated on 2017-05-19: Mallinckrodt Spokesperson Responds to Jim Chanos Short, Tells Benzinga His Thesis 'is not based on fact and is misleading'

Financial news for MNK dated on 2017-05-18: Kyniko Manager Chanos Says Alliance Between Mallinckrodt and Express Scripts Could Hurt Investors

Financial news for MNK dated on 2017-05-18: Kynikos' Jim Chanos, at SALT, Says He's Short Mallinckrodt, Express Scripts

Financial news for MNK dated on 2017-05-18: Mallinckrodt, Express Scripts Shares Make Brief Dip to Session Lows, Quickly Rebound

Financial news for MNK dated on 2017-05-08: Mallinckrodt Q1 EPS \$1.68 vs \$1.63 Est, Sales \$810.9 vs \$781.2M Est

Financial news for MNK dated on 2017-05-04: Mallinckrodt Announces First Patient Enrolled in Phase 2 Trial of StrataGraft

Financial news for MNK dated on 2017-04-05: Wall Street Journal Reports Mallinckrodt Leaves Pharmaceutical Trade Group Ahead of Potential Changes to Bylaws

Financial news for MNK dated on 2017-04-03: Mallinckrodt Says It Has Reached \$35M Settlement With U.S. Over Monitoring Of Controlled Substances

Financial news for MNK dated on 2017-03-22: Martin Shkreli Posts On Facebook That He Has No Position In Mallinckrodt, But 'Short Conspiracies Are Insane', Has Acthar Down 20% YoY In His Model From Here On Out And Believes Company Is Fairly Valued

Financial news for MNK dated on 2017-03-22: UPDATE: Martin Shkreli Tells Benzinga 'Shorts Have Been Talking About Acthar Problems For 5 Years, Docs Swear it's A Reasonable Last-Line Treatment And I've Heard Many Testimonials About it Rescuing Patients, Much Ado About Nothing Here'

Financial news for MNK dated on 2017-03-21: Hedge Fund Manager Whitney Tilson Says It's Good To See More Scrutiny Of Mallinckrodt and H.P. Acthar, Says Company Appears To Be Scummy and Scammy

Financial news for MNK dated on 2017-03-20: Mallinckrodt Finalizes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately \$203 Million

Financial news for MNK dated on 2017-03-13: Citron's Andrew Left On CNBC Says Mallinckrodt Is A Small Short Position For Him Following Valeant News

Financial news for MNK dated on 2017-03-10: Mallinckrodt Shares Volatile Over Last Few Mins, Moving Lower, Despite Traders Circulating Unconfirmed Takeover Chatter

Financial news for MNK dated on 2017-03-01: Mallinckrodt plc Board Increases Company's Share Repurchase Plan by \$1.0 Billion

Financial news for MNK dated on 2017-02-22: Canaccord Genuity Initiates Coverage On

Mallinckrodt plc Ordinary Shares at Buy

Financial news for MNK dated on 2017-02-16: Recent Weakness In Mallinckrodt Being Attributed To Recently Published Business Insider Article On Acthar Gel

Financial news for MNK dated on 2017-02-15: Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma

Financial news for MNK dated on 2017-02-07: Mallinckrodt On Conf. Call Says They Expect To Realize Net Of 4.5% On The 6.9% Price Increase Of Acthar When Adjusting For Both Rebates and Discounts

Financial news for MNK dated on 2017-02-07: Mallinckrodt Sees FY 2017 EPS \$7.40 to \$8.00 vs \$7.70 Est

Financial news for MNK dated on 2017-02-07: Mallinckrodt Q1 EPS \$1.91 vs \$1.82 Est, Revenue \$829.9M vs \$826.9M Est

Financial news for MNK dated on 2017-02-06: Watching Shares Of Mallinckrodt As Traders Passing Around Short Piece By Agloe Capital

Financial news for MNK dated on 2017-01-27: Mallinckrodt Shares Resumed, Now Up 1.05%

Financial news for MNK dated on 2017-01-27: Mallinckrodt Shares Halted Pending News

Financial news for MNK dated on 2017-01-19: Shares Of Mallinckrodt Up 2.7% Off The Open, FDA Document Being Passed Around By Traders Regarding Acthar Gel Is A Synthetic That Was Never Marketed, Unrelated To Mallinckrodt

Financial news for MNK dated on 2017-01-18: Mallinckrodt Release Confirms FTC Resolution Related to Questcor Matter

Financial news for MNK dated on 2017-01-18: Martin Shkreli Gives Benzinga Full Statement Following Report of Mallinckrodt Suit by FTC

Financial news for MNK dated on 2017-01-18: FTC Has Said Mallinckrodt Will Pay \$100M to Settle Commission, State Charges Related to Allegations Co. Maintained Monopoly of Specialty Drugs

Financial news for MNK dated on 2017-01-18: Mallinckrodt Shares Halted News Pending

Financial news for MNK dated on 2017-01-18: Mallinckrodt Shares Halted on Circuit Breaker, Now Down 13%

Financial news for MNK dated on 2017-01-09: Mesoblast Sells 20.04M Shares to Mallinckrodt for \$21.7M, Was Previously Rumored

Financial news for MNK dated on 2016-12-22: Hearing Mesoblast, Mallinckrodt Entered Deal In which Mallinckrodt Will Buy 20.04M Shares of Mesoblast's Ordinary Shares at \$1.4761/Share

Financial news for MNK dated on 2016-11-18: Raymond James Initiates Coverage On Mallinckrodt at Outperform

Financial news for MNK dated on 2016-08-12: Stifel Nicolaus Initiates Coverage on Mallinckrodt at Buy

Financial news for MNK dated on 2016-06-29: BMO Capital Initiates Coverage on Mallinckrodt at Outperform

Financial news for MNK dated on 2016-06-06: Goldman Sachs Initiates Coverage on Mallinckrodt at Neutral, Announces \$73.00 PT

Financial news for MNK dated on 2016-05-03: Piper Jaffray Maintains Overweight on Mallinckrodt, Raises PT to \$102.00

Financial news for MNK dated on 2016-03-28: RBC Capital Maintains Outperform on Mallinckrodt, Raises PT to \$218.00

Financial news for MNK dated on 2016-02-19: Wells Fargo Initiates Coverage on Mallinckrodt at Outperform

Financial news for MNK dated on 2016-02-03: Mizuho Securities Upgrades Mallinckrodt to Buy

Financial news for MNK dated on 2015-12-03: Morgan Stanley Upgrades Mallinckrodt to Overweight, Raises PT to \$88.00

Financial news for MNK dated on 2015-11-09: Mallinckrodt Study Shows Acthar Primary Endpoint Not Met in Patients with Persistently Active Systemic Lupus Erythematosus

Financial news for MNK dated on 2015-10-14: Northland Securities Initiates Coverage on Mallinckrodt at Outperform, Announces \$92.00 PT

Financial news for MNK dated on 2015-08-10: UPDATE: Mallinckrodt Pharmaceuticals to Acquire Therakos from Gores Group for \$1.325B

Financial news for MNK dated on 2015-08-05: JP Morgan Downgrades Mallinckrodt to Neutral, Lowers PT to \$120.00

Financial news for MNK dated on 2015-07-29: Bellerophon Therapeutics Expands License Agreement With INO Therapeutics

Financial news for MNK dated on 2015-04-28: Goldman Sachs Reinstates Neutral on Mallinckrodt, Announces \$131.00 PT

Financial news for MNK dated on 2015-03-05: Mallinckrodt Pharmaceuticals to Acquire Ikaria for \$2.3B

Financial news for MNK dated on 2015-02-13: JP Morgan Upgrades Mallinckrodt to Overweight, Raises PT to \$130.00

Financial news for MNK dated on 2015-01-06: BMO Capital Downgrades Mallinckrodt to Market Perform, Maintains \$95.00 PT

Financial news for MNK dated on 2014-11-19: Mallinckrodt PLC Reports Q4 EPS of \$1.68 vs \$1.41 Est; Revenue of \$789.30M vs \$757.86M Est

Financial news for MNK dated on 2014-10-15: Morgan Stanley Maintains Equal-weight on Mallinckrodt PLC, Announces \$97.00 PT

Financial news for MNK dated on 2014-10-14: Mallinckrodt PLC Sees FY2014 EPS \$6.70-7.20 vs \$6.63 Est; Sees Sales \$3.65B-3.75B

Financial news for MNK dated on 2014-09-22: Barclays Reinstates Overweight on Mallinckrodt PLC, Announces \$105.00 PT

Financial news for MNK dated on 2014-08-07: Mallinckrodt PLC Reports Q3 EPS of \$1.20 Which May Not Compare \$0.87 Est; Revenue of \$653.10M Which May Not Compare \$278.83M Est

Financial news for MNK dated on 2014-07-16: Oppenheimer Initiates Coverage on Mallinckrodt PLC at Outperform, Announces \$100.00 PT

Financial news for MNK dated on 2014-05-08: Mallinckrodt Reports Q2 Adjusted EPS of \$0.95 vs \$0.77 Est; Revenue of \$557.80M vs \$566.48M Est

Financial news for MNK dated on 2014-04-25: CRT Capital Upgrades Mallinckrodt PLC to Fair Value, Raises PT to \$70.00

Financial news for MNK dated on 2014-04-24: CRT Capital Upgrades Mallinckrodt PLC to Fairly Valued, Raises PT to \$70.00

Financial news for MNK dated on 2014-04-09: UBS Upgrades Mallinckrodt PLC to Buy, Raises PT to \$84.00

Financial news for MNK dated on 2014-04-08: BMO Capital Upgrades Mallinckrodt PLC to Outperform, Raises PT to \$71.00

Financial news for MNK dated on 2014-04-07: Mallinckrodt to Acquire Questcor Pharmaceuticals for \$5.6B

Financial news for MNK dated on 2014-02-12: Morgan Stanley Downgrades Mallinckrodt PLC to Equal-weight, Removes \$63.00 PT

Financial news for MNK dated on 2014-02-11: UPDATE: Mallinckrodt to Acquire Cadence Pharmaceuticals for \$14.00/Share in Cash

Financial news for MNK dated on 2014-02-07: Morgan Stanley Maintains Overweight on Mallinckrodt PLC, Raises PT to \$63.00

Financial news for MNK dated on 2014-01-13: Mallinckrodt, Medtronic Announce Clinical and Commercial Collaboration

Financial news for MNK dated on 2014-01-08: Morgan Stanley Initiates Coverage on Mallinckrodt PLC at Overweight, Announces \$60.00 PT

Financial news for MNK dated on 2013-12-04: Buckingham Research Initiates Coverage on Mallinckrodt PLC at Buy, Announces \$63.00 PT

Financial news for MNK dated on 2013-11-26: Jefferies Initiates Coverage on Mallinckrodt PLC at Buy, Announces \$60.00 PT

Financial news for MNK dated on 2013-11-07: Mallinckrodt PLC Reports Q4 EPS of \$1.02 vs \$0.85 Est; Revenue of \$552.20M vs \$572.57M Est

Financial news for MNK dated on 2013-09-17: Goldman Sachs Initiates Coverage on Mallinckrodt PLC at Neutral, Announces \$45.00 PT

Financial news for MNK dated on 2013-08-09: Mallinckrodt PLC Reports Q3 EPS of \$0.49 vs \$0.78 Est; Revenue of \$570.0M vs \$560.17M Est

Financial news for MNK dated on 2013-07-08: UPDATE: Barclays Capital Initiates Mallinckrodt at Equal-Weight on Differentiated Platform Value

Financial news for MNK dated on 2013-07-03: UPDATE: Bank of America Initiates Mallinckrodt with Buy on Brand Launch Potential

Financial news for MNK dated on 2013-07-01: Mallinckrodt Begins Trading on NYSE